All News

New drug approvals, toxicity management, and pharmacists’ roles in cancer care all dominated the top oncology articles of 2022.

Both benefits and concerns exist, but implementing policies and regulations promotes employee productivity, guards safety.

Products include a vaccine for meningococcal disease and a new type of COVID-19 test.

From newsworthy moments to groundbreaking research, these were the most-read articles on Pharmacy Times in 2022.

Can you relate?

Products range from acne treatment to cough relief.

Cases address anticoagulants and medication administration.

First direct evidence of diminished 5-HT release proves hypothesis, according to a new analysis published in Biological Psychiatry.

Develop New Year's resolutions that include empowering patients, enhancing communication, increasing professional development.

Pain management and the opioid epidemic dominated the top health system articles in 2022.

This year, retail pharmacists were interested in diabetes research, saving patients money, and influenza vaccine candidates.

Without company or insurance contracts, controlled medication prices reduce burden on patients.

The National Institute of Health’s grant funds a phase 2 clinical trial of doxycycline in a large group of individuals with the 2 conditions who are smokers or used to smoke.

Steve Simske, PhD, discusses his research investigating how the occurrence of discrimination in biology can act as an agnostic analogy for discrimination in humans’ social environments.

In 10 states, the data showed more than 26% of women had limited accessibility to mammography, primarily in the Rocky Mountains and the South.

Participants who survived Hodgkin lymphoma as children showed signs of being biologically older than their peers, with a heightened risk of cognitive problems.

The phase 2 GO29781 study showed that 80% of patients who had received at least 2 prior therapies achieved durable response rates with mosunetuzumab-axgb treatment.

Jawad Saleh, PharmD, BSPharm, BCCCP, BCPS, clinical manager of Pharmacy Services at the Hospital for Special Surgery, discusses how pharmacists can treat postoperative nausea and vomiting.

Can a brand name manufacturer be held liable for damages caused by a drug product manufactured by another firm?

Results show possible impact of using Janssen Pharmaceuticals’ ibrutinib in the front-line setting, providing additional data on chronic lymphocytic leukemia therapies.

From newsworthy moments to groundbreaking research, these are the most popular articles in the zoster space, published on Pharmacy Times® during 2022.

Intravenous tocilizumab (Actemra; Genentech) has been approved for the treatment of COVID-19 in individuals who are hospitalized and receiving systemic corticosteroids and supplemental oxygen.

The FDA approved lenacapavir, which is the first approval of a drug in a new class of antiretrovirals for the treatment of HIV-1 called capsid inhibitors.

The FDA's approval includes the group indication for all current and future EGFR TKIs, including erlotinib, osimertinib, and gefitinib.

HOPA DEI Committee chair Kamakshi Rao, PharmD, BCOP, FASHP, noted that on the DEI journey ahead, the oncology pharmacist should be front and center as part of the treatment team.

But many patients pay more than necessary because of PBMs, patent abuses, IQVIA data shows.

The analysis found that individuals in underserved communities were as much as 34% less likely to be vaccinated against COVID-19.

Calcitriol may offer protection from the harmful effects of the chemical in drinking water, analysis shows.

The protein is vitally important and could be a prognostic indicator and potential therapeutic target.

TD2 remission is defined as a hemoglobin A1C level of less than 6.5% at least 1 year after stopping medication, investigators say.